Showing results (191-200 of 829) with videos related to
Sort By:
Pageof 83
Diabetes Care|August 23, 2022
Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical TrialViktor Rotbain Curovic, Mie Klessen Eickhoff, Teemu Rönkkö, et al.Current Diabetes Reports|November 23, 2006
Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural historyPeter RossingKidney International|January 3, 2018
YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrologyFrederik Persson, Rikke BorgDiabetes Care|March 1, 2003
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria studyKasper Rossing, Per K Christensen, Steen Andersen, et al.Cardiovascular Diabetology|August 28, 2013
24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional studySimone Theilade, Maria Lajer, Tine Willum Hansen, et al.Clinical Pharmacology and Therapeutics|October 22, 2024
Effect of Dapagliflozin on Measured vs. Panel-Estimated Glomerular Filtration RateEsben Iversen, Line Juel Nielsen, Viktor Rotbain Curovic, et al.The New England Journal of Medicine|January 31, 2003
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetesPeter Gaede, Pernille Vedel, Nicolai Larsen, et al.Journal of the American Society of Nephrology : JASN|September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR TrialHiddo J L Heerspink, Di Xie, George Bakris, et al.Plos One|March 17, 2023
Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuriaChristina Gjerlev Poulsen, Daniel G K Rasmussen, Federica Genovese, et al.The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Pageof 83